Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Biomedical Engineering
SJR: 0.207 SNIP: 0.376 CiteScore™: 0.79

ISSN Druckformat: 0278-940X
ISSN Online: 1943-619X

Volumen 47, 2019 Volumen 46, 2018 Volumen 45, 2017 Volumen 44, 2016 Volumen 43, 2015 Volumen 42, 2014 Volumen 41, 2013 Volumen 40, 2012 Volumen 39, 2011 Volumen 38, 2010 Volumen 37, 2009 Volumen 36, 2008 Volumen 35, 2007 Volumen 34, 2006 Volumen 33, 2005 Volumen 32, 2004 Volumen 31, 2003 Volumen 30, 2002 Volumen 29, 2001 Volumen 28, 2000 Volumen 27, 1999 Volumen 26, 1998 Volumen 25, 1997 Volumen 24, 1996 Volumen 23, 1995

Critical Reviews™ in Biomedical Engineering

DOI: 10.1615/CritRevBiomedEng.2016016141
pages 347-369

Stealth Engineering for In Vivo Drug Delivery Systems

Ankita Mohapatra
Department of Electrical and Computer Engineering, University of Memphis, Memphis, TN 38152
Bashir I. Morshed
Department of Electrical and Computer Engineering, University of Memphis, Memphis, TN 38152
Warren O. Haggard
Chair Excellence Associate Dean, Department of Biomedical Engineering, University of Memphis, Memphis, TN 38152
Richard A. Smith
Department of Orthopedic Surgery & Biomedical Engineering, University of Tennessee Campbell Clinic, Memphis, TN 38163


In generic terms, a drug delivery substrate (DDS) can be described as a vehicle to transport drug to the point of interest. A DDS that would ideally have the capability to control drug dosage and achieve target specificity, localization, and higher therapeutic efficacy has been pursued as a holy grail in pharmaceutical research. Over the years, diverse classes, structures, and modifications of DDS have been proposed to achieve this aim. One of its major deterrents, however, is rapid elimination of drug by the immune system before intended functionality. Stealth engineering is broadly defined as a method of designing a drug carrier to minimize or delay opsonization until the encapsulated drug is delivered to the intended target. Stealth-engineered DDS has been successful in extending drug circulation lifetime from a few minutes to several days. Currently, this field of research has made much progress since its initiation in 1960s with liposomes to DNA boxes. Activity has also benefited several areas of medicine, where it has been applied in cancer, gene therapy, bone regrowth, and infection treatment. This review covers the progress of some types of DDS that have been published and indexed in major databases (including ScienceDirect, PubMed, and Google Scholar) in the scientific literature.

Articles with similar content:

Strategies and Therapeutic Opportunities for the Delivery of Drugs to the Esophagus
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 3
Hannah Batchelor, Liang Zhang, Barbara R. Conway, Danielle Russell
Oral Delivery of HIV-Protease Inhibitors
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.17, 2000, issue 2
Barbra H. Stewart, Lilian Y. Li, David Fleisher
Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine’s Drug Conjugates on Cancer Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 1
Sathish Dyawanapelly, Animesh Kumar, Manish K. Chourasia
Cutting Eugenics Out of CRISPR-Cas9
Ethics in Biology, Engineering and Medicine: An International Journal, Vol.6, 2015, issue 3-4
Marya Pollack, Robert Pollack, Carolyn Brokowski
Heparan Sulfate-based Treatments for Regenerative Medicine
Critical Reviews™ in Eukaryotic Gene Expression, Vol.21, 2011, issue 1
Victor Nurcombe, Bina Rai, Simon M. Cool